La cadena de opciones muestra datos clave de las opciones de acciones de Digi Power X a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Digi Power X..

Digi Power X (NASDAQ:DGXX) Bolsa, Cadena de Opciones

Digi Power X

Digi Power X Inc is an infrastructure company that develops cutting-edge data centers to drive the expansion of sustainable energy assets. The company focuses on expanding power infrastructure to create a resilient backbone for the future of energy and technology.

Supermicro,Sign,At,Headquarters,In,San,Jose,,California,,Usa,-

News

Movers

Tech

DGXX

NVDA

SMCI

Las acciones de Super Micro sube por menor presión regulatoria, nuevos avances en IA y pausa en restricciones a China.

¿Qué está pasando con las acciones de Super Micro el lunes?

Digi Power X Inc. - Common Subordinate Voting Shares

Digi Power X Inc

<p><strong>Figma Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIG#NYSE">FIG</a>) shares traded higher Friday, continuing to draw investor attention after a volatile debut session on Thursday that saw the stock surge over 250% <a href="https://www.benzinga.com/markets/equities/25/08/46785080/jim-cramer-calls-figma-too-expensive-at-50x-sales-stock-surges-250-on-market-debut">following its initial public offering. </a></p>
<p><strong>What To Know</strong>: The stock briefly reached $143.45 in after-hours trading before pulling back.</p>
<p>Figma priced its IPO at $33 per share, raising approximately $1.2 billion and valuing the company at over $19 billion. The offering consisted of nearly 37 million shares and was priced above an already upwardly revised range. Despite sharp gains on day one, Friday&#8217;s trading showed signs of cooling momentum as shares gave up part of their early advance.</p>
<p>Investor interest in Figma is being fueled by strong revenue growth and widespread enterprise adoption. The company reported $749 million in revenue for 2024, up 48% year-over-year and $228.2 million in first-quarter 2025, representing 46% growth from the year prior. Figma counts 95% of Fortune 500 companies and major tech clients such as Microsoft, Alphabet and Salesforce among its customers. It ended 2024 with a net dollar retention rate of 134%.</p>
<p>Still, not everyone is convinced by the valuation. </p>
<p>CNBC host<strong> Jim Cramer</strong> repeatedly warned on social media that Figma was "way too expensive," trading at nearly 54 times sales based on a 40% growth rate. He advised investors to avoid placing market orders and predicted a pullback, calling it one of the most expensive stocks in the market.</p>
<p>Despite those warnings, the IPO defied expectations, reinforcing investor appetite for high-growth tech names amid renewed optimism in the broader tech sector. </p>
<p>Figma's debut follows the collapse of a $20 billion acquisition deal by Adobe, which was scrapped due to regulatory pressure. Now trading independently, Figma has quickly become one of the most closely watched post-IPO stocks, with some market watchers suggesting it could take on meme stock status in the coming weeks.</p>
<p>Friday afternoon, the stock appeared to be stabilizing after its initial surge, trading modestly higher but far below its first-day peak.</p>
<p><strong>FIG Price Action:</strong> Figma shares closed Friday up 5.63% at $122, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a></p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/markets/macro-economic-events/25/08/46805962/trump-russia-medvedev-nuclear-submarines-vix-index-wall-street">Trump Issues Nuclear Threat To Russia–And Wall Street&#8217;s Fear Gauge Goes Vertical</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


Figma Shares Edge Higher After Explosive IPO Debut, Despite Valuation Concerns

<p>CIBC  analyst Scott Fletcher   maintains Colliers International Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIGI#NASDAQ">CIGI</a>) with a Outperformer and raises the price target from $149 to $175.</p>


Price Target

Analyst Ratings

CIGI

CIBC Maintains Outperformer on Colliers International Gr, Raises Price Target to $175

NTHI

On July 28, NeOnc Technologies Enters Subscription Agreement With Quazar And Nuromena;  Quazar To Purchase 2,500,000 Nuromena Shares For $400,000;  Co's Holding In Nuromena Reduced To 80%

ABAT

American Battery Technology Says Contract Terminated To Sell Legacy Property In Fernley, Nevada; On July 28, Purchase Agreement Terminated Without Penalties

<p>Canaccord Genuity  analyst Jeremy Hoy   maintains New Gold (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NGD#TSX">NGD</a>) with a Buy and raises the price target from C$8.25 to C$9.</p>


TSX:NGD

Canaccord Genuity Maintains Buy on New Gold, Raises Price Target to C$9

<p><a href="https://www.bloomberg.com/news/articles/2025-08-01/apple-ceo-tells-staff-ai-is-ours-to-grab-in-hourlong-pep-talk?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-08-01/apple-ceo-tells-staff-ai-is-ours-to-grab-in-hourlong-pep-talk?embedded-checkout=true</a></p>


General

AAPL

'Apple CEO Tells Staff AI Is 'Ours to Grab' in Hourlong Pep Talk'- Bloomberg

<p><strong>BRC</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) is set to give its latest quarterly earnings report on Monday, 2025-08-04. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that BRC will report an <strong>earnings per share</strong> (EPS) of $-0.03. </p>
<p>Anticipation surrounds BRC's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.02, leading to a 25.74% drop in the share price the following trading session.</p>
<p>Here's a look at BRC's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.02</td>
<td>-0.05</td>
<td>-0.02</td>
<td>-0.02</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.04</td>
<td>-0.03</td>
<td>-0.01</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-26.0%</td>
<td>-16.0%</td>
<td>4.0%</td>
<td>-38.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754082431_0.png" alt="eps graph" /></p>
<h3>Market Performance of BRC's Stock</h3>
<p>Shares of BRC were trading at $1.7 as of July 31. Over the last 52-week period, shares are down 67.65%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analyst Observations about BRC</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding BRC.</p>
<p>Analysts have given BRC a total of 3 ratings, with the consensus rating being Outperform. The average one-year price target is $4.0, indicating a potential 135.29% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Hain Celestial Group, Mama's Creations and Laird Superfood, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Hain Celestial Group, with an average 1-year price target of $2.63, suggesting a potential 54.71% upside.</li>
<li>Analysts currently favor an Buy trajectory for Mama's Creations, with an average 1-year price target of $10.0, suggesting a potential 488.24% upside.</li>
<li>Analysts currently favor an Buy trajectory for Laird Superfood, with an average 1-year price target of $12.0, suggesting a potential 605.88% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Hain Celestial Group, Mama's Creations and Laird Superfood, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRC</td>
<td>Outperform</td>
<td>-8.56%</td>
<td>$32.47M</td>
<td>-23.72%</td>
</tr>
<tr>
<td>Hain Celestial Group</td>
<td>Neutral</td>
<td>-10.95%</td>
<td>$84.65M</td>
<td>-17.93%</td>
</tr>
<tr>
<td>Mama's Creations</td>
<td>Buy</td>
<td>18.15%</td>
<td>$9.18M</td>
<td>4.82%</td>
</tr>
<tr>
<td>Laird Superfood</td>
<td>Buy</td>
<td>17.61%</td>
<td>$4.88M</td>
<td>-1.18%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>BRC ranks at the bottom for Revenue Growth and Gross Profit among its peers. However, it has the highest Return on Equity. Overall, BRC's performance is mixed compared to its peers, with strengths in profitability but weaknesses in revenue growth.</p>
<h3>All You Need to Know About BRC</h3>
<p>BRC Inc is a veteran-controlled company that serves premium coffee, content, and merchandise to active military, veterans, and first responders. It is committed to producing great coffee that consumers love, and high-quality merchandise that enables its community to showcase its brand. Its omnichannel distribution has three components: Direct to Consumer channel includes its e-commerce business, through which consumers order products online and products are shipped to them, Its wholesale channel includes products sold to an intermediary such as convenience, grocery, drug, and mass merchandise stores, who in turn sell those products to consumers, and Outpost channel includes revenue from its Company-operated and franchised Black Rifle Coffee retail coffee shop locations.</p>
<h3>Unraveling the Financial Story of BRC</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Challenges:</strong> BRC's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-8.56%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> BRC's net margin excels beyond industry benchmarks, reaching <strong>-3.21%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> BRC's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-23.72%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> BRC's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-1.28%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>8.92</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/BRCC/earnings"><strong>To track all earnings releases for BRC visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

BRCC

An Overview of BRC's Earnings

<h3>Gainers</h3>
<ul>
<li><strong>ATA Creativity Global</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) shares rose 46.3% to $1.58 during Friday's after-market session. The company's market cap stands at $69.8 million. </li>
<li><strong>Lobo EV Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares moved upwards by 15.99% to $0.91. The market value of their outstanding shares is at $4.2 million. </li>
<li><strong>REE Automotive</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) stock moved upwards by 7.76% to $0.71. The company's market cap stands at $18.4 million. </li>
<li><strong>Birks Group</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares moved upwards by 6.2% to $0.72. The market value of their outstanding shares is at $13.8 million. </li>
<li><strong>Denny's</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DENN#NASDAQ">DENN</a>) shares rose 5.65% to $3.8. The market value of their outstanding shares is at $190.6 million. </li>
<li><strong>GrowGeneration</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) stock moved upwards by 5.27% to $1.03. The company's market cap stands at $58.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>EZGO Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) shares fell 17.3% to $0.41 during Friday's after-market session. The company's market cap stands at $1.9 million. </li>
<li><strong>Lixiang Education Hldg</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEH#NASDAQ">LXEH</a>) stock fell 5.91% to $2.71. The company's market cap stands at $2.4 million. </li>
<li><strong>Fitell</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) shares declined by 5.2% to $0.51. The market value of their outstanding shares is at $10.4 million. </li>
<li><strong>Lazydays Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) shares decreased by 4.9% to $4.27. The market value of their outstanding shares is at $18.4 million. </li>
<li><strong>JX Luxventure Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXG#NASDAQ">JXG</a>) stock decreased by 3.96% to $0.97. The company's market cap stands at $4.5 million. </li>
<li><strong>Mixed Martial Arts Group</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock decreased by 3.94% to $0.98. The company's market cap stands at $12.7 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AACG

DENN

EZGO

FTEL

GORV

GRWG

LOBO

LXEH

12 Consumer Discretionary Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Psyence Biomedical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares rose 38.4% to $3.89 during Friday's after-market session. The company's market cap stands at $3.5 million. </li>
<li><strong>Ontrak</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares increased by 28.04% to $0.4. The market value of their outstanding shares is at $2.1 million. </li>
<li><strong>Exicure</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares rose 21.99% to $8.4. The market value of their outstanding shares is at $45.0 million. </li>
<li><strong>ProPhase Labs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock rose 10.33% to $0.36. The market value of their outstanding shares is at $14.9 million. </li>
<li><strong>Inotiv</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) stock moved upwards by 7.8% to $2.07. The company's market cap stands at $69.0 million. </li>
<li><strong>InspireMD</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) shares increased by 7.8% to $2.9. The company's market cap stands at $85.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Adial Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares decreased by 13.9% to $0.39 during Friday's after-market session. The company's market cap stands at $6.8 million. </li>
<li><strong>Equillium</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) stock declined by 8.61% to $0.65. The market value of their outstanding shares is at $13.9 million. </li>
<li><strong>GlucoTrack</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares declined by 8.51% to $5.7. The market value of their outstanding shares is at $3.4 million. </li>
<li><strong>Praxis Precision Medicine</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) shares decreased by 8.41% to $49.5. The company's market cap stands at $1.1 billion. </li>
<li><strong>Y-mAbs Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) stock fell 7.29% to $4.2. The market value of their outstanding shares is at $202.4 million. </li>
<li><strong>Tenon Medical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares declined by 6.85% to $1.36. The company's market cap stands at $7.7 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ADIL

GCTK

NOTV

NSPR

OTRK

PRAX

PRPH

TNON

XCUR

YMAB

12 Health Care Stocks Moving In Friday's After-Market Session

<p>GUIYANG, China, Aug. 1, 2025 /PRNewswire/ -- Full Truck Alliance Co. Ltd. ("FTA" or the&nbsp;"Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YMM#NYSE">YMM</a>), a leading digital freight platform, today announced changes to its freight brokerage service.</p>
<p>To ensure sustainability of its freight brokerage service, the Company has decided to increase the service fee rate for freight brokerage service to reduce such service's reliance on government grants and potential uncertainties. The Company understands that such changes may increase costs to shippers. The Company expects that, starting from the quarter ending September 30, 2025, the transaction volume of its freight brokerage service will significantly decline, resulting in a decline in revenue from freight brokerage service, while the cost of revenue for such service will increase, which may adversely affect the Company's profit to certain extent.</p>


Full Truck Alliance To Increase The Service Fee Rate For Freight Brokerage Service

<h3>Gainers</h3>
<ul>
<li><strong>Freightos</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) shares moved upwards by 16.3% to $3.36 during Friday's after-market session. The market value of their outstanding shares is at $140.1 million. </li>
<li><strong>Addentax Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>) shares moved upwards by 8.78% to $0.43. The market value of their outstanding shares is at $3.0 million. </li>
<li><strong>Webus International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETO#NASDAQ">WETO</a>) stock rose 5.29% to $1.79. The market value of their outstanding shares is at $40.0 million. </li>
<li><strong>SKYX Platforms</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYX#NASDAQ">SKYX</a>) stock increased by 4.47% to $1.05. The market value of their outstanding shares is at $106.9 million. </li>
<li><strong>Nuvve Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) stock rose 4.26% to $0.55. The market value of their outstanding shares is at $8.4 million. </li>
<li><strong>Euro Tech Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLWT#NASDAQ">CLWT</a>) stock increased by 4.09% to $1.27. The company's market cap stands at $9.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Galaxy Payroll Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) shares fell 7.6% to $0.55 during Friday's after-market session. The company's market cap stands at $10.8 million. </li>
<li><strong>Intelligent Living</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) shares decreased by 5.67% to $0.45. The company's market cap stands at $8.3 million. </li>
<li><strong>WANG &amp; LEE Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares declined by 5.41% to $0.05. The market value of their outstanding shares is at $1.6 million. </li>
<li><strong>Tigo Energy</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYGO#NASDAQ">TYGO</a>) stock declined by 5.35% to $1.24. The company's market cap stands at $81.8 million. As per the press release, Q2 earnings came out 3 days ago. </li>
<li><strong>Fusion Fuel Green</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) stock declined by 4.32% to $5.1. The company's market cap stands at $4.5 million. </li>
<li><strong>Ryde Group</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) shares declined by 3.81% to $0.29. The company's market cap stands at $10.2 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ATXG

CLWT

CRGO

GLXG

HTOO

ILAG

NVVE

RYDE

SKYX

TYGO

WETO

WLGS

12 Industrials Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Lantronix</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) stock rose 10.5% to $3.25 during Friday's after-market session. The market value of their outstanding shares is at $124.8 million. </li>
<li><strong>RingCentral</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) shares rose 6.6% to $25.19. The market value of their outstanding shares is at $2.3 billion. </li>
<li><strong>BTCS</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) shares moved upwards by 5.31% to $4.26. The company's market cap stands at $218.6 million. </li>
<li><strong>Trident Digital Tech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) stock moved upwards by 4.65% to $1.35. The market value of their outstanding shares is at $94.8 million. </li>
<li><strong>Cemtrex</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) stock increased by 4.31% to $1.21. The market value of their outstanding shares is at $4.1 million. </li>
<li><strong>Sequans Communications</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) stock moved upwards by 4.0% to $1.3. The market value of their outstanding shares is at $179.8 million. As per the press release, Q2 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>HeartCore Enterprises</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCR#NASDAQ">HTCR</a>) shares fell 9.4% to $0.44 during Friday's after-market session. The market value of their outstanding shares is at $11.1 million. </li>
<li><strong>Mega Fortune Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRT#NASDAQ">MGRT</a>) shares decreased by 5.83% to $3.07. The company's market cap stands at $33.8 million. </li>
<li><strong>Amtech Systems</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASYS#NASDAQ">ASYS</a>) shares fell 5.19% to $4.32. The market value of their outstanding shares is at $67.3 million. </li>
<li><strong>Global Engine Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLE#NASDAQ">GLE</a>) shares decreased by 3.96% to $0.94. The market value of their outstanding shares is at $19.3 million. </li>
<li><strong>Ultra Clean Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) stock fell 3.88% to $21.44. The company's market cap stands at $1.0 billion. As per the news, the Q2 earnings report came out 4 days ago. </li>
<li><strong>Peraso</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) shares fell 3.49% to $0.8. The market value of their outstanding shares is at $4.2 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ASYS

BTCS

CETX

HTCR

LTRX

MGRT

PRSO

SQNS

TDTH

UCTT

12 Information Technology Stocks Moving In Friday's After-Market Session

<p>UFP Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPT#NASDAQ">UFPT</a>) is preparing to release its quarterly earnings on Monday, 2025-08-04. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect UFP Techs to report an <strong>earnings per share</strong> (EPS) of $2.27.</p>
<p>The announcement from UFP Techs is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.46 in the last quarter, leading to a 0.08% increase in the share price on the following day.</p>
<p>Here's a look at UFP Techs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.01</td>
<td>2.13</td>
<td>1.81</td>
<td>1.53</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.47</td>
<td>2.46</td>
<td>2.39</td>
<td>1.86</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>-10.0%</td>
<td>4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754082379_0.png" alt="eps graph" /></p>
<h3>Market Performance of UFP Techs's Stock</h3>
<p>Shares of UFP Techs were trading at $226.39 as of July 31. Over the last 52-week period, shares are down 24.41%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/UFPT/earnings"><strong>To track all earnings releases for UFP Techs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


UFPT

What to Expect from UFP Techs's Earnings

<p>Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) will release its quarterly earnings report on Monday, 2025-08-04. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Praxis Precision Medicine to report an <strong>earnings per share</strong> (EPS) of $-3.37.</p>
<p>The market awaits Praxis Precision Medicine's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company missed EPS by $0.09, which was followed by a 0.0% drop in the share price the next day.</p>
<p>Here's a look at Praxis Precision Medicine's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-3.20</td>
<td>-2.96</td>
<td>-1.99</td>
<td>-2.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-3.29</td>
<td>-2.94</td>
<td>-2.75</td>
<td>-1.74</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>-41.0%</td>
<td>5.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754082365_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Praxis Precision Medicine were trading at $54.22 as of July 31. Over the last 52-week period, shares are up 1.07%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PRAX/earnings"><strong>To track all earnings releases for Praxis Precision Medicine visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What to Expect from Praxis Precision Medicine's Earnings

<p>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) will release its quarterly earnings report on Monday, 2025-08-04. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Prothena Corp to report an <strong>earnings per share</strong> (EPS) of $-1.52.</p>
<p>The market awaits Prothena Corp's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.09, leading to a 4.65% increase in the share price the following trading session.</p>
<p>Here's a look at Prothena Corp's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.03</td>
<td>-1.04</td>
<td>-1.18</td>
<td>-1.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.12</td>
<td>-1.08</td>
<td>-1.10</td>
<td>1.22</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>5.0%</td>
<td>2.0%</td>
<td>-1.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754082312_0.png" alt="eps graph" /></p>
<h3>Performance of Prothena Corp Shares</h3>
<p>Shares of Prothena Corp were trading at $6.87 as of July 31. Over the last 52-week period, shares are down 65.57%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analysts' Take on Prothena Corp</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Prothena Corp.</p>
<p>Prothena Corp has received a total of 8 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $36.75, the consensus suggests a potential 434.93% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Myriad Genetics and Lexicon Pharmaceuticals, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Myriad Genetics, with an average 1-year price target of $7.67, suggesting a potential 11.64% upside.</li>
<li>Analysts currently favor an Buy trajectory for Lexicon Pharmaceuticals, with an average 1-year price target of $4.0, suggesting a potential 41.78% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for Myriad Genetics and Lexicon Pharmaceuticals are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rigel Pharmaceuticals</td>
<td>Neutral</td>
<td>80.58%</td>
<td>$48.92M</td>
<td>104.74%</td>
</tr>
<tr>
<td>Myriad Genetics</td>
<td>Neutral</td>
<td>-3.12%</td>
<td>$134.20M</td>
<td>-0.01%</td>
</tr>
<tr>
<td>Lexicon Pharmaceuticals</td>
<td>Buy</td>
<td>11.68%</td>
<td>$1.23M</td>
<td>-18.81%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Prothena Corp ranks highest in Gross Profit among its peers. It is in the middle for Revenue Growth and Return on Equity.</p>
<h3>About Prothena Corp</h3>
<p>Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.</p>
<h3>Prothena Corp: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Prothena Corp displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>5556.0%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-2128.54%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Prothena Corp's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-13.02%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Prothena Corp's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-11.55%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.02</strong>, Prothena Corp adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/PRTA/earnings"><strong>To track all earnings releases for Prothena Corp visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PRTA

A Glimpse of Prothena Corp's Earnings Potential

<p>Canaccord Genuity  analyst Susan Anderson   maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Buy and raises the price target from $542 to $600.</p>


ULTA

Canaccord Genuity Maintains Buy on Ulta Beauty, Raises Price Target to $600

<p>Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) is gearing up to announce its quarterly earnings on Monday, 2025-08-04. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Syndax Pharmaceuticals will report an <strong>earnings per share</strong> (EPS) of $-0.99.</p>
<p>Syndax Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS beat by $0.29 in the last quarter, leading to a 21.59% drop in the share price on the following day.</p>
<p>Here's a look at Syndax Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.27</td>
<td>-1.08</td>
<td>-1.11</td>
<td>-0.91</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.98</td>
<td>-1.10</td>
<td>-0.98</td>
<td>-0.80</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-22.0%</td>
<td>-7.000000000000001%</td>
<td>8.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754082266_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Syndax Pharmaceuticals were trading at $9.92 as of July 31. Over the last 52-week period, shares are down 49.24%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SNDX/earnings"><strong>To track all earnings releases for Syndax Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SNDX

Syndax Pharmaceuticals's Earnings: A Preview

<p>B&amp;G Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) is gearing up to announce its quarterly earnings on Monday, 2025-08-04. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that B&amp;G Foods will report an <strong>earnings per share</strong> (EPS) of $0.06.</p>
<p>Anticipation surrounds B&amp;G Foods's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company missed EPS by $0.12, which was followed by a 5.08% drop in the share price the next day.</p>
<p>Here's a look at B&amp;G Foods's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.16</td>
<td>0.30</td>
<td>0.20</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.04</td>
<td>0.31</td>
<td>0.13</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>3.0%</td>
<td>-20.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754082252_0.png" alt="eps graph" /></p>
<h3>B&amp;G Foods Share Price Analysis</h3>
<p>Shares of B&amp;G Foods were trading at $4.1 as of July 31. Over the last 52-week period, shares are down 50.54%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Insights Shared by Analysts on B&amp;G Foods</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding B&amp;G Foods.</p>
<p>The consensus rating for B&amp;G Foods is Neutral, based on 3 analyst ratings. With an average one-year price target of $4.67, there's a potential 13.9% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of  and Mama's Creations, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Mama's Creations, with an average 1-year price target of $10.0, suggesting a potential 143.9% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for  and Mama's Creations are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>B&amp;G Foods</td>
<td>Neutral</td>
<td>-10.48%</td>
<td>$90.09M</td>
<td>0.16%</td>
</tr>
<tr>
<td>Mama's Creations</td>
<td>Buy</td>
<td>18.15%</td>
<td>$9.18M</td>
<td>4.82%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>B&amp;G Foods ranks lower in Revenue Growth compared to its peers. It also has lower Gross Profit and Return on Equity. Overall, B&amp;G Foods is positioned at the bottom among its peers based on the provided metrics.</p>
<h3>Unveiling the Story Behind B&amp;G Foods</h3>
<p>B&amp;G Foods Inc is an American packaged-food manufacturer. It operate in a single industry segment and manufacture, sell and distribute a diverse portfolio of high-quality shelf-stable and frozen foods across the United States, Canada and Puerto Rico. Its products include frozen and canned vegetables, vegetable, canola and other cooking oils, vegetable shortening, cooking sprays, oatmeal and other hot cereals, fruit spreads, canned meats and beans, bagel chips, spices, seasonings, hot sauces, wine vinegar, The company's main brands are Ac'cent, B&amp;G, B&amp;M, Baker's Joy, Bear Creek Country Kitchens, Cary's, Cream of Rice, Cream of Wheat, Devonsheer, Don Pepino, Durkee, Emeril's, Grandma's Molasses, MacDonald's.</p>
<h3>A Deep Dive into B&amp;G Foods's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> B&amp;G Foods's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately <strong>-10.48%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> B&amp;G Foods's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>0.2%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> B&amp;G Foods's ROE excels beyond industry benchmarks, reaching <strong>0.16%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> B&amp;G Foods's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.03%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>4.01</strong>, B&amp;G Foods faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/BGS/earnings"><strong>To track all earnings releases for B&amp;G Foods visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Uncovering Potential: B&G Foods's Earnings Preview

<p>Two years ago, <strong>Carvana Co. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) had more in common with a junkyard relic than a growth stock. Following a peak at $376.83 in August 2021, shares plummeted to as low as $3.55 as of December 2022, a 99% eradication that kept bankruptcy rumors swirling louder than its hallmark <a href="https://www.benzinga.com/markets/earnings/25/07/46747642/carvana-cashed-in-on-trumps-tariffs-saw-100-per-car-uplift-from-tariff-related-tailwinds-in-q2-despite-industry-wide-struggle">car vending machines.</a></p>
<p><strong>Check out CVNA stock's rise&nbsp;<a href="https://www.benzinga.com/quote/CVNA" target="_blank" rel="noreferrer noopener">here</a>.</strong></p>
<p>But in a plot turn, <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46774414/carvanas-unbelievable-flip-stock-crashed-99-then-exploded-11000">Carvana staged a 11,000%+ comeback</a>, finishing Thursday at $413.34—its all-time high. That ranks among the most dramatic comebacks in recent market history.</p>
<p>And now a <a href="https://www.benzinga.com/etfs">fresh crop of ETFs </a>can be riding shotgun on Carvana&#8217;s comeback ride.</p>
<h2 class="wp-block-heading">From Clunker To Comeback King</h2>
<p>Carvana&#8217;s recovery wasn&#8217;t an anomaly. The company performed a complete teardown and rebuild in 2023, reducing debt, restructuring operations, embracing AI-powered pricing, and investing in its logistics network.</p>
<p>But the actual turbocharge? Tariffs. American duties on foreign-made cars lifted new car prices, sending buyers to lower-priced used cars, the very segment where Carvana is strongest.</p>
<p>This &#8220;tariff tailwind&#8221; juiced Carvana&#8217;s gross profit per unit, particularly in April, and <a href="https://www.benzinga.com/markets/earnings/25/07/46739500/carvana-q2-earnings-revenue-eps-beat-estimates-as-vehicle-sales-jump-41-company-sees-enormous-opportunity-ahead">set the stage for its Q2 beat</a>.</p>
<p>What ensued was a market melt-up: analysts rushed to raise price targets, meme-stock chatter resurfaced, and momentum traders descended on the trade.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46765236/carvana-shifts-into-high-gear-after-q2-beat-analysts-boost-price-targets">Carvana Shifts Into High Gear After Q2 Beat, Analysts Boost Price Targets</a></strong></p>
<h2 class="wp-block-heading">The ETF Angle</h2>
<p>Carvana&#8217;s rocket ride is now echoing across a number of ETFs, both sector and thematic. Here&#8217;s who&#8217;s riding the slipstream:</p>
<ul class="wp-block-list">
<li><strong>Defiance Daily Target 2× Long Carvana ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVNX#NASDAQ">CVNX</a>): This pure-play 2× leveraged ETF gives 2× daily performance of CVNA, so it&#8217;s a favorite among thrill-seeking traders. As Carvana soared after earnings, CVNX surged 35%+. Best for short-term momentum trades, but hold on tight—this one&#8217;s not for Sunday drivers.</li>
</ul>
<ul class="wp-block-list">
<li><strong>ProShares Online Retail ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONLN#NYSE">ONLN</a>): As a significant holding, ONLN provides diversified exposure to online-first retailers. The ETF sits poised to profit from the increasing move toward e-commerce, even for high-ticket purchases such as cars.</li>
<li><strong>Consumer Discretionary Select Sector SPDR Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>): This consumer discretionary titan offers wider exposure with some CVNA presence. Less oomph than CVNX or ONLN, but more even risk-adjusted returns for long-term investors.</li>
</ul>
<h2 class="wp-block-heading">But What&#8217;s The Catch?</h2>
<p>Carvana&#8217;s valuation has soared into orbit, 67× forward earnings, according to <a href="https://www.benzinga.com/pro/register">Benzinga Pro</a>. Any tech glitch or macro shock (credit tightening, for example) would pop the rally quickly.</p>
<p>However, the tale is no longer speculative. Carvana is demonstrating profits, digital logistics at Scaler, pricing power through AI. And a consumer tailwind fueled by macro policy changes.</p>
<h2 class="wp-block-heading">Bottom Line</h2>
<p>Carvana&#8217;s 11,000% surge isn&#8217;t simply a meme-driven miracle, but a master lesson in change, fueled by tariffs, technology, and determination. And now, ETF investors have more options than ever to strap themselves in for the ride, whether they want to take it easy (XLY), go for a clever thematic spin (ONLN), or give it flat-out torque (CVNX).</p>
<p>Either way, this is more than just traffic noise.</p>
<p><strong>CVNA Price Action:</strong> Carvana shares were down 5.74% during regular trading and up 0.33% in after-hours trading on Friday<a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">, according to Benzinga Pro data.</a></p>
<p><strong>Read Next:<a href="https://www.benzinga.com/etfs/specialty-etfs/25/08/46807334/eurozone-gdp-growth-etfs-game"> </a></strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/etfs/specialty-etfs/25/08/46807334/eurozone-gdp-growth-etfs-game">Eurozone GDP Growth Pops A Surprise: These ETFs Are Winning The Game</a></strong></li>
</ul>
<p><em>Photo: Around the World Photos / Shutterstock.com</em></p>


Specialty ETFs

ETFs

CVNA

CVNX

ONLN

Select Sector SPDR-Consumer Discretionary

Carvana's Comeback Drives These ETFs Into The Limelight—Tariff Tailwinds Add Fuel

Offerings

XTIA

XTI Aerospace Files For Mixed Shelf Of Up To $1B

Press Releases

Digi Power X Announces Grant of Stock Options

Digi Power X Issues Letter to Shareholders

Economics

Digi Power X Reports 45% Month-Over-Month Increase in Cash and Crypto Position with no Long-Term Debt and Reports June 2025 Production Results

Financing

Digi Power X Announces Proposed Shares for Debt Settlement with NANO Nuclear Energy

AI & Technology Virtual Investor Conference Agenda Announced for July 10th

AI & Technology Virtual Investor Conference: Presentations Now Available for Online Viewing

Digi Power X Acquires Supermicro NVIDIA B200 Systems to Launch Tier 3 NeoCloud AI Infrastructure

Digi Power X Announces $15 Million Registered Direct Offering of Common Stock

Digi Power X Announces Closing of $15 Million Registered Direct Offering of Common Stock

Legal

Digi Power X Subsidiary, US Data Centers Inc., Files Provisional Patent for ARMS 200 Modular AI Data Center Platform

Comments

Digi Power X

Digi Power X (DGXX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL